Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Active not recruiting 5Recruiting 4

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 81Genitourinary 75Other hematologic neoplasm 73Gastrointestinal 62Breast 52Thoracic 49CNS 45Gynecologic 29Myeloid 27Head & Neck 25Sarcoma 19Tumor-Agnostic 17Plasma cell 17Dermatologic 16Other solid neoplasm 13Endocrine 8NET 4Classical hematology 3Other 2Other neoplasm 1

Conditions

Neuroendocrine Tumors 2Uveal Melanoma 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neoplasm Metastasis 1Multiple Sclerosis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Melanoma 1Breast Neoplasms 1Brain Neoplasms 1Advanced Lung Neuroendocrine Tumor 1Adrenocortical Carcinoma 1Adenoma, Islet Cell 1Adenocarcinoma of Lung 1

Interventions

lutetium Lu 177 dotatate 15Magnetic Resonance Spectroscopy 9Everolimus 8gallium Ga 68 dotatate 6lanreotide 4cabozantinib 4Temozolomide 4Specimen Handling 4Nivolumab 4Lutetium-177 4Lutetium 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4surufatinib 3olaparib 3copper dotatate CU-64 3Somatostatin 3Injections 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Capecitabine 3pembrolizumab 2fludarabine phosphate 2fludarabine 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sunitinib 2Radiosurgery 2Octreotide 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Specimen Handling × NET × Clear all
NCT05773274 2026-05-26

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT06788886 2025-12-30

Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

Mayo Clinic

Phase NA Recruiting
147 enrolled
CNSEndocrineGenitourinaryNET

Brain Neoplasms, Multiple Sclerosis, Prostatic Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡